TG Therapeutics and Ildong Pharmaceutical have signed a licensing deal for the development and commercialisation of Ublituximab in South Korea and South-East Asia.

Under the deal, Ildong will gain exclusive rights for all therapeutic indications of Ublituximab in the region.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

By offering the drug licence, TG Therapeutics will earn a $2m upfront payment, in addition to sales-based milestone and royalty payments.

"Having already demonstrated impressive clinical activity in patients with relapsed and refractory chronic lymphocytic leukemia, Ublituximab has shown itself to be a promising treatment for patients with B-cell related disorders."

TG Therapeutics chairman and interim CEO Michael Weiss said, "Having already demonstrated impressive clinical activity in patients with relapsed and refractory chronic lymphocytic leukemia, Ublituximab has shown itself to be a promising treatment for patients with B-cell related disorders."

Ublituximab is being developed by TG Therapeutics for treating hematologic malignancies and other B-cell lymphoproliferative disorders.

See Also:

At present, a North American Phase I/II trial is assessing the chimeric monoclonal antibody in relapsed or refractory non-Hodgkin’s lymphoma patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ildong chairman and CEO Jung-Chi Lee said the inclusion of Ublituximab in its biologics pipeline is a strategic fit for the company.

"We believe Ublituximab, a next generation anti-CD20 therapy, will strengthen our presence in oncology and auto-immune areas and look forward to working with TG Therapeutics in developing Ublituximab in South Korea and South-East Asia," Lee added.

MedCI acted as the licensing advisor to TG Therapeutics and provided assistance for the transaction.

Ublituximab carries orphan status for B-cell chronic lymphocytic leukemia in both Europe and the US.